Albireo Pharma (NASDAQ:ALBO)‘s stock had its “buy” rating reaffirmed by research analysts at Cowen in a note issued to investors on Wednesday, AnalystRatings.com reports.
Other analysts have also issued research reports about the stock. Wedbush set a $69.00 price target on shares of Albireo Pharma and gave the company a “buy” rating in a research note on Sunday, March 10th. BidaskClub upgraded shares of Albireo Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, March 6th. HC Wainwright started coverage on shares of Albireo Pharma in a research note on Thursday, February 28th. They set a “buy” rating and a $62.00 price target for the company. ValuEngine upgraded shares of Albireo Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, February 28th. Finally, Zacks Investment Research lowered shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research note on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $53.40.
NASDAQ:ALBO opened at $32.98 on Wednesday. Albireo Pharma has a one year low of $19.10 and a one year high of $37.95. The company has a market cap of $384.35 million, a P/E ratio of -8.37 and a beta of 1.72.
Albireo Pharma (NASDAQ:ALBO) last posted its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.18). The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $1.94 million. Albireo Pharma had a negative return on equity of 32.42% and a negative net margin of 361.94%. Analysts predict that Albireo Pharma will post -5.74 earnings per share for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Alps Advisors Inc. increased its stake in Albireo Pharma by 30.6% in the 4th quarter. Alps Advisors Inc. now owns 27,659 shares of the biopharmaceutical company’s stock worth $678,000 after acquiring an additional 6,478 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Albireo Pharma by 11.4% during the 3rd quarter. BlackRock Inc. now owns 584,177 shares of the biopharmaceutical company’s stock worth $19,255,000 after purchasing an additional 59,901 shares during the last quarter. Fosun International Ltd purchased a new stake in Albireo Pharma in the fourth quarter valued at about $4,492,000. Bank of New York Mellon Corp raised its stake in Albireo Pharma by 8.6% in the third quarter. Bank of New York Mellon Corp now owns 35,023 shares of the biopharmaceutical company’s stock valued at $1,154,000 after buying an additional 2,760 shares during the last quarter. Finally, Sectoral Asset Management Inc raised its stake in Albireo Pharma by 21.3% in the fourth quarter. Sectoral Asset Management Inc now owns 229,978 shares of the biopharmaceutical company’s stock valued at $5,641,000 after buying an additional 40,400 shares during the last quarter. Hedge funds and other institutional investors own 66.85% of the company’s stock.
About Albireo Pharma
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.